Pawan Singh, MD
Neurology · Columbus, OHNPI 1588003131
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Novocure Inc. at 37.9% of the total. Reporting peaked in 2023 at $2,594 and has fallen 67.9% since, to $832 in 2025.
Across 187 payments — averaging $39.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$3K
- AbbVie$800
- SK Life Science, Inc.$593
- Sumitomo Pharma America, Inc.$434
- Teva Pharmaceuticals USA, Inc.$405
- Neurocrine Biosciences, Inc.$191
- plus $2K from 25 others
Across 13 payments — averaging $4589.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$60K
What the payments were for
- Food & beverage$7,27298%
- Education$1492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 28 | $2,810 |
| AbbVie(2 entities) | 36 | $800 |
| SK Life Science, Inc. | 16 | $593 |
| Sumitomo Pharma America, Inc. | 16 | $434 |
| Teva Pharmaceuticals USA, Inc. | 12 | $405 |
| Neurocrine Biosciences, Inc. | 8 | $191 |
| UCB, Inc. | 7 | $190 |
| AstraZeneca(2 entities) | 3 | $165 |
| Pfizer | 14 | $160 |
| Monteris Medical Corporation | 2 | $156 |
| Eisai Inc. | 2 | $150 |
| Argenx US, Inc. | 5 | $148 |
| Amgen | 2 | $138 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $128 |
| Telix Pharmaceuticals | 1 | $119 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $112 |
| Servier Pharmaceuticals LLC | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Bristol Myers Squibb | 4 | $87 |
| Sunovion Pharmaceuticals Inc. | 4 | $59 |
| Biogen | 3 | $58 |
| Octapharma USA, Inc. | 2 | $55 |
| BTG International Inc. | 1 | $50 |
| Novartis | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $24 |
| Avion Pharmaceuticals | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,421 in reported general payments places this provider in the 70th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 83 | $1,535 |
| Memantine Hcl | 93 | $1,094 |
| Ondansetron Hcl | 21 | $1,022 |
| Gabapentin | 49 | $390 |
| Atorvastatin Calcium | 18 | $210 |
| Phenytoin Sodium Extended | 13 | $175 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 26 | $146 |
| Quetiapine Fumarate | 18 | $126 |
| Primidone | 11 | $108 |
| Escitalopram Oxalate | 16 | $45 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $33 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.